Enhancement of thrombolytic therapy with deglycosylated forms of

Details Enhancement of thrombolytic therapy with deglycosylated forms of Enhancement of thrombolytic therapy with deglycosylated forms of

1995-06-05

1997-06-10

Jacobson, Dian C.

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

424 9464, 435212, 435215, 435216, 435217, 435226, A61K 3848, A61K 3849, C12N 964, C12N 968

Patent

active

056372990

ABSTRACT:
This invention provides an improved method for enhancing the activity of thrombolytic agents, including t-PA, scu-PA, tcu-PA, streptokinase, acylated plasminogen-streptokinase activator complex (APSAC), mixtures of these, and other activators of plasminogen. The enhancement method comprises supplementation of plasma plasminogen levels with deglycosylated forms of glu- and lys-plasminogen. Deglycosylated plasminogen refers herein to glu- or lys-plasminogen 2 having a single oligosaccharide chain at Thr.sub.345, plasminogens having a single oligosaccharide chain at Asn.sub.288, and unglycosylated forms of plasminogen. The work described herein shows that a less glycosylated form of plasminogen (glu-plasminogen 2) has a higher affinity for fibrin clots than a more glycosylated plasminogen (glu-plasminogen 1). Based on this work, it is believed that glycosylation of plasminogen inhibits binding of plasminogen to fibrin clots, perhaps due to steric hindrance, and further, that deglycosylated forms of plasminogen may be more effective enhancers of scu-PA in thrombolytic therapy than fully glycosylated forms of plasminogen. Improved enhancement of the activity of thrombolytic agents allows the use of lower therapeutic doses and thus, is expected to relieve some of the bleeding and other side effects of thrombolytic therapy.

REFERENCES:
patent: 4996050 (1991-02-01), Tsukada et al.
Lijnen et al., "On the Role of the Carbohydrate Side Chains of Human Plasminogen in Its interaction with .alpha..sub.2 -Antiplasmin and Fibrin", Eur. J. Biochem. 120:149-154 (1981).
Takada et al., "Glu-Plasminogen I and II: Their Activation by Urokinase and Streptokinase in the Presence of Fibrin and Fibrinogen:," Thrombosis Research 39:289-296 (1985).
Pannell et al., "Complementary Modes of Action of Tissue-Type Plasminogen Activator and Pro-urokinase by which Their Synergistic Effect on Clot Lysis May be Exaplained", J. Clin. Invest., 81:853-859 (1988).
Watahiki et al., "Potentiation by Lys-Plasminogen of Clot Lysis by Single or Two Chain Urokinase-Type Plasminogen Activator or Tissue-Type Plasminogen Activator", Thrombosis and Haemostasis 61(3):502-506 (1989).
Stack et al., "Effect of desialylation on the biological properties of human plasminogen", Biochem J. 284:81-86 (1992).
Davidson, Donald J. et al., "Plasminogen Activator Activities of Equimolar Complexes of Streptokinase with Variant Recombinant Plasminogens," Biochemistry, 29:3585-3590 (1990).
Kumarasamy, R. J. Chromatography 512:149-155 (1990).
deVries, C. et al., J. Biol. Chem. 265(23):13547-13552 (1990).
Badylak, S.F. et al., Thrombosis Research 62:115-126 (1991).

Affiliated with

Also associated with

Rating

Enhancement of thrombolytic therapy with deglycosylated forms of does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhancement of thrombolytic therapy with deglycosylated forms of, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of thrombolytic therapy with deglycosylated forms of will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-762972